[go: up one dir, main page]

PE20080674A1 - Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico - Google Patents

Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico

Info

Publication number
PE20080674A1
PE20080674A1 PE2007001310A PE2007001310A PE20080674A1 PE 20080674 A1 PE20080674 A1 PE 20080674A1 PE 2007001310 A PE2007001310 A PE 2007001310A PE 2007001310 A PE2007001310 A PE 2007001310A PE 20080674 A1 PE20080674 A1 PE 20080674A1
Authority
PE
Peru
Prior art keywords
growth factor
factor receptor
epidermal growth
enhance
effect
Prior art date
Application number
PE2007001310A
Other languages
English (en)
Inventor
Molina Luis Enrique Fernandez
Hidalgo Greta Garrido
Rodriguez Rolando Perez
Ramirez Belinda Sanchez
Gomez Audry Fernandez
Requena Alejandro Lopez
Delgado Irene Beausoleil
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40223744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080674(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of PE20080674A1 publication Critical patent/PE20080674A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN ANTICUERPO HUMANIZADO CONTRA EL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO (EGFR) hR3 PRODUCIDO POR LA LINEA CELULAR CON NUMERO DE DEPOSITO 951110101; B) UNO O MAS INTERFERONES DE TIPO 1 TAL COMO INF-a HUMANO RECOMBINANTE. SE REFIERE TAMBIEN A UN JUEGO DE REACTIVOS QUE CONTIENE UN VIAL CON EL ANTICUERPO, UNO O MAS VIALES CON UNO O MAS INTERFERONES E INSTRUCCIONES PARA SU ADMINISTRACION. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE CANCER
PE2007001310A 2006-09-29 2007-09-27 Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico PE20080674A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060190A CU23612A1 (es) 2006-09-29 2006-09-29 Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico

Publications (1)

Publication Number Publication Date
PE20080674A1 true PE20080674A1 (es) 2008-07-23

Family

ID=40223744

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001310A PE20080674A1 (es) 2006-09-29 2007-09-27 Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico

Country Status (19)

Country Link
US (1) US20100047207A1 (es)
EP (1) EP2070547B1 (es)
KR (1) KR101482957B1 (es)
CN (2) CN102940883A (es)
AR (1) AR063011A1 (es)
AU (1) AU2007302429B2 (es)
BR (1) BRPI0717142A2 (es)
CA (1) CA2664795C (es)
CL (1) CL2007002797A1 (es)
CO (1) CO6160338A2 (es)
CR (1) CR10753A (es)
CU (1) CU23612A1 (es)
MA (1) MA30811B1 (es)
MX (1) MX2009003159A (es)
PE (1) PE20080674A1 (es)
TN (1) TN2009000104A1 (es)
TR (1) TR200902344T1 (es)
UY (1) UY30616A1 (es)
WO (1) WO2008037225A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI500630B (zh) * 2008-06-20 2015-09-21 Centro Inmunologia Molecular 具有細胞生長抑制功效之表皮生長因子受體（ｅｇｆｒ）抑制劑類及彼等於腫瘤治療上之用途
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
MY188446A (en) * 2015-07-27 2021-12-09 Innocimab Pte Ltd Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
DE69324671D1 (de) * 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
BR0209147A (pt) * 2001-05-08 2004-06-08 Merck Patent Gmbh Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
US20060134064A1 (en) * 2004-12-20 2006-06-22 David Goldstein Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions

Also Published As

Publication number Publication date
AR063011A1 (es) 2008-12-23
CA2664795C (en) 2014-06-17
BRPI0717142A2 (pt) 2013-10-15
EP2070547B1 (en) 2013-04-24
CN101678099A (zh) 2010-03-24
KR20090058566A (ko) 2009-06-09
CO6160338A2 (es) 2010-05-20
EP2070547A1 (en) 2009-06-17
CL2007002797A1 (es) 2008-04-18
CA2664795A1 (en) 2008-04-03
AU2007302429B2 (en) 2013-10-03
TN2009000104A1 (en) 2010-08-19
CU23612A1 (es) 2010-12-08
CN102940883A (zh) 2013-02-27
EP2070547A4 (en) 2011-11-02
MX2009003159A (es) 2009-04-06
CR10753A (es) 2009-10-15
MA30811B1 (fr) 2009-10-01
TR200902344T1 (tr) 2009-08-21
WO2008037225A1 (es) 2008-04-03
KR101482957B1 (ko) 2015-01-15
AU2007302429A1 (en) 2008-04-03
US20100047207A1 (en) 2010-02-25
UY30616A1 (es) 2008-05-02

Similar Documents

Publication Publication Date Title
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
CL2009001277A1 (es) Anticuerpo que enlaza especificamente el flt3 humano; fragmento de cualquiera de los anticuerpos antes dichos; acido polinucleico aislado; vector de expresion; celula recombinante; composicion farmaceutica y sus usos; producto que contiene el anticuerpo para tratar cancer
EA201492053A1 (ru) Белки фактора роста фибробластов 21
BR112018008805A2 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
MX365525B (es) Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
PE20050339A1 (es) Anticuerpos humanos modificados anti-igf-1r
CU23734A1 (es) Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
CL2012002536A1 (es) Composición farmacéutica que comprende un anticuerpo anti-factor de crecimiento nervioso (ngf) o un fragmento de unión al antígeno de éste, un amortiguador histidina 5 a 60mm, polisorbato 80 0,01% a 0,1%, y un ph entre 5,0 y 6,0; composición liofilizada; dispositivo; artículo de manufactura; y su uso en enfermedades mediadas por ngf, tales como trastornos del dolor.
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BRPI0710671B8 (pt) uso de um vetor de bacteriofágo viral adenoassociado (aavp) terapêutico para a fabricação de um medicamento para o tratamento e profilaxia de uma doença hiperproliferativa
PE20091655A1 (es) Farmaco para el cancer de higado
PE20140616A1 (es) Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri)
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
CO2020008308A2 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
CL2011001860A1 (es) Compuestos derivados de indol; procedimiento de preparacion de dichos compuestos; composicion y combinacion farmaceutica; y uso en el tratamiento del cancer.
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
BR112023004020A2 (pt) Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
EA202190102A1 (ru) Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака
MX2023011166A (es) Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
EA201992272A1 (ru) Ацилированное инсулиновое соединение

Legal Events

Date Code Title Description
FC Refusal